Wellgistics Health (NASDAQ:WGRX) and TheracosBio Partner to Expand Nationwide, PBM-Free Access to Brenzavvy(R), an FDA-Approved Diabetes Therapy, Through 6,500+ Pharmacies

About this update from Wellgistics Health, Inc.

[{"type":"text","content":"TAMPA, FL / ACCESS Newswire / September 30, 2025 / Wellgistics Health, Inc. ("Wellgistics Health" or the "Company") (NASDAQ:WGRX), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced a strategic collaboration with TheracosBio, the manufacturer of Brenzavvy® (bexagliflozin), to make diabetes medications more affordable and accessible across the U.S. healthcare system.","length":472,"tagName":"p"},{"type":"text","content":"The joint effort leverages Wellgistics Health's "maker-to-taker" platform - a direct pipeline that connects manufacturers to pharmacies and patients while bypassing costly intermediaries. With over 6,500 independent and chain pharmacies in its national network, Wellgistics Health will expand access to Brenzavvy through both traditional retail and direct-to-patient delivery models.","length":397,"tagName":"p"},{"type":"text","content":"Key Benefits of the Collaboration","length":33,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Expanded Access - Brenzavvy will be made available through the Wellgistics Health network of 6,500+ independent pharmacies, as well as participating chain pharmacies, reaching patients nationwide.","length":196,"tagName":"p"}]},{"val":[{"type":"text","content":"Affordability - By eliminating middlemen, this initiative is expected to lower costs to levels often below typical insurance copayments, easing patient cost burdens and increasing adherence.","length":190,"tagName":"p"}]},{"val":[{"type":"text","content":"Pharmacist Empowerment - Participating pharmacies will provide patient counseling, adherence support, and care coordination.","length":124,"tagName":"p"}]},{"val":[{"type":"text","content":"AI & Technology Integration - The Wellgistics Tech & Hub platform, powered by AI-driven modules, will streamline eligibility checks, claims adjudication, adherence tracking, and reporting.","length":196,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":706,"olType":false},{"type":"text","content":"Addressing an Urgent Need","length":25,"tagName":"p"},{"type":"text","content":"Type 2 diabetes affects over 37 million Americans and costs the U.S. an estimated $327 billion annually. Yet only one in eight eligible adults receives an SGLT-2 ...

More updates from Wellgistics Health, Inc.